Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines


TÜRK S., MALKAN Ü. Y. , TÜRK C. , Hocaoğlu H., Mutlu D., Güneş G., ...More

Sage Open Medicine, vol.5, 2017 (Journal Indexed in ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 5
  • Publication Date: 2017
  • Doi Number: 10.1177/2050312116689519
  • Title of Journal : Sage Open Medicine
  • Keywords: Ankaferd hemostat, anticancer, melanoma, MEDICINAL-PLANT EXTRACT, CONTROLLED CLINICAL-TRIAL, PARTIAL NEPHRECTOMY MODEL, RENAL TUBULAR APOPTOSIS, BLOOD STOPPER, IN-VITRO, PULPOTOMY, AGENTS, ABS

Abstract

Objective: Ankaferd hemostat is the first topical hemostatic agent about the red blood cell-fibrinogen relations tested in the clinical trials. Ankaferd hemostat consists of standardized plant extracts including Alpinia) officinarum, Glycyrrhiza glabra, Thymus vulgaris, Urtica dioica, and Vitis vinifera. The aim of this study was to determine the effect of Ankaferd hemostat on viability of melanoma cell lines.